Here's Why Veracyte (VCYT) is a Strong Growth Stock

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score emphasizes a company's financial health and future growth potential [4] - Momentum Score focuses on stocks with upward or downward price trends [5] - VGM Score combines all three styles to highlight stocks with the best overall characteristics [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [9] Stock Recommendation: Veracyte (VCYT) - Veracyte is a diagnostics company specializing in cancer detection and treatment, with a diverse portfolio of genomic tests [12] - VCYT holds a 2 (Buy) rating on the Zacks Rank and has a VGM Score of B, indicating strong growth potential [13] - The company is projected to achieve year-over-year earnings growth of 4.2% for the current fiscal year, with upward revisions in earnings estimates [13] - VCYT's average earnings surprise stands at 515.9%, making it a compelling option for growth investors [13][14]